Drug Profile
NC 2500
Alternative Names: NC-2500Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Nippon Chemiphar
- Class Antigouts
- Mechanism of Action Xanthine dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hyperuricaemia
Highest Development Phases
- No development reported Gout; Hyperuricaemia
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for phase-I development in Gout(In volunteers) in Japan (PO)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Hyperuricaemia(In volunteers) in Japan (PO)
- 13 Jun 2018 NC 2500 is still in phase I trials for Hyperuricemia(PO) in Japan